Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Enfortumab Vedotin After PD-1 or PD-L1 Inhibitors in Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma (EV‑201): A Multicentre, Single-Arm, Phase 2 TrialLancet Oncol 2021 May 12;[EPub Ahead of Print], EY Yu, DP Petrylak, PH O'Donnell, JL Lee, MS van der Heijden, Y Loriot, MN Stein, A Necchi, T Kojima, MR Harrison, S Hoon Park, DI Quinn, EI Heath, JE Rosenberg, J Steinberg, SY Liang, J Trowbridge, M Campbell, B McGregor, AV Balar
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.